Bruce Ksander

Gregory, MS, S. Koh, E. Huang, R.R.Saff, A Marshak-Rothstein, S. Mukai, and Ksander BR. A novel treatment for ocular tumors using membrane Fas ligand vesicles to activate innate immunity and terminate immune privilege. Invest. Ophthalmol. Vis. Sci. 46:2495-2502, 2005.

Thompson JA, Dissanayake SK, Ksander BR, Knutson KL, Disis ML, and Ostrand-Rosenberg S. Tumor cells transduced with the MHC Class II transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain. Cancer Research. 66: 1147 – 1154, 2006.

Chen P, and Ksander BR. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines. Current Eye Research. 31:43-55, 2006.

Chen P, T Uno, and Ksander BR. Requirement of CD80+ costimulation for rejection of ocular tumors and termination of immune privilege. Experimental Eye Research. (In press January 2006).

Chen P, T Uno, and Ksander BR. Tumor escape mutants develop within an immune privileged environment in the absence of T cell selection. J Immunol. (In press March 2006).

Chen P, and Ksander BR. Influence of immune surveillance and immune privilege on the formation of intraocular tumors – “Immune Response and the Eye, 2nd Edition, ed, JY Niederkorn, and H Kaplan. Chemical Immunology Basel, Karger. (In press, March 2006)